Clinical trial
A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks.
NCT01541579 is registered in ClinicalTrials.gov with Tigenix S.A.U. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks.
- Lead sponsor
- Tigenix S.A.U.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2012
- Completion date
- November 30, 2016
- Enrollment
- 278 (estimated)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease